Parathyroid hormone (PTH) (Preotact®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000464
English
Authors' recommendations:
Parathyroid hormone (Preotact®) is recommended for restricted use within NHS Wales for the treatment of postmenopausal women with osteoporosis at high risk of fractures. It should be considered as an alternative to teriparatide only in patients who are intolerant of that agent†, or where the storage or administration issues are deemed to provide significant added benefit. It should only be initiated by specialists experienced in the treatment of osteoporosis.
Details
Project Status:
Completed
Year Published:
2007
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=85245&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.